Engineering Immune Organoids to Study Pediatric Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 25
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
Brain tumors
Renal tumors
Neuroblastoma
Disqualifiers
Any histology not mentioned in the inclusion criteria
Adult patient or parents/guardians incapable/incapable of giving its/their consent
Patients deprived of their liberty by a judicial or administrative decision
Trial design
Design model
Single group
Treatments tested in this trial
Skin biopsy
Procedure/SurgerySkin biopsy
Fresh tumor sample
Procedure/SurgeryFresh tumor sample
Blood sample
Biological/VaccineBlood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
Healthy tissue from the tumor
Procedure/SurgeryHealthy tissue from the tumor site whenever possible
Spinal cerebrospinal fluid (SCF)
Procedure/SurgerySpinal cerebrospinal fluid (SCF) whenever possible
Treatment groups
108 Participants
are divided into 1 treatment groupGroup A: Immune organoids from pediatric patient tissues using iPSCOther 5 interventions
Trial outcomes
Primary outcomes
1
Proportion of viable and exploitable immune organoids with engrafted tumor cells
Time frame
until 5 years after enrolmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov